PMC:7195088 / 64233-65191 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"683","span":{"begin":75,"end":83},"obj":"Species"},{"id":"950","span":{"begin":89,"end":97},"obj":"Disease"}],"attributes":[{"id":"A683","pred":"tao:has_database_id","subj":"683","obj":"Tax:9606"},{"id":"A950","pred":"tao:has_database_id","subj":"950","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Owing to the lack of high-level evidence, administration of tocilizumab in patients with COVID-19 should preferentially occur within the framework of RCT. Off-label use according to local protocols and consent procedures may be considered only in those COVID-19 patients excluded from RCT (or hospitalized where RCT are not available or still to be implemented) and who are worsening while receiving standard supportive care (in the absence of concomitant/superimposed infections). In our opinion, this could be a reasonable off-label use of tocilizumab in these early phases of the COVID-19 pandemic, although patients and physicians should be fully aware that currently there is only a non–peer-reviewed, noncomparative, observational experience (very low evidence from an unreviewed cases series), and that it only supports a potential favourable effect on inflammatory signs and symptoms, while there is no information on any possible effect on survival."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T371","span":{"begin":89,"end":97},"obj":"Disease"},{"id":"T372","span":{"begin":253,"end":261},"obj":"Disease"},{"id":"T373","span":{"begin":469,"end":479},"obj":"Disease"},{"id":"T374","span":{"begin":583,"end":591},"obj":"Disease"}],"attributes":[{"id":"A371","pred":"mondo_id","subj":"T371","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A372","pred":"mondo_id","subj":"T372","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A373","pred":"mondo_id","subj":"T373","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A374","pred":"mondo_id","subj":"T374","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Owing to the lack of high-level evidence, administration of tocilizumab in patients with COVID-19 should preferentially occur within the framework of RCT. Off-label use according to local protocols and consent procedures may be considered only in those COVID-19 patients excluded from RCT (or hospitalized where RCT are not available or still to be implemented) and who are worsening while receiving standard supportive care (in the absence of concomitant/superimposed infections). In our opinion, this could be a reasonable off-label use of tocilizumab in these early phases of the COVID-19 pandemic, although patients and physicians should be fully aware that currently there is only a non–peer-reviewed, noncomparative, observational experience (very low evidence from an unreviewed cases series), and that it only supports a potential favourable effect on inflammatory signs and symptoms, while there is no information on any possible effect on survival."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T357","span":{"begin":159,"end":164},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T358","span":{"begin":512,"end":513},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T359","span":{"begin":529,"end":534},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T360","span":{"begin":686,"end":687},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T361","span":{"begin":692,"end":696},"obj":"http://purl.obolibrary.org/obo/CLO_0008416"},{"id":"T362","span":{"begin":692,"end":696},"obj":"http://purl.obolibrary.org/obo/CLO_0050081"},{"id":"T363","span":{"begin":827,"end":828},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Owing to the lack of high-level evidence, administration of tocilizumab in patients with COVID-19 should preferentially occur within the framework of RCT. Off-label use according to local protocols and consent procedures may be considered only in those COVID-19 patients excluded from RCT (or hospitalized where RCT are not available or still to be implemented) and who are worsening while receiving standard supportive care (in the absence of concomitant/superimposed infections). In our opinion, this could be a reasonable off-label use of tocilizumab in these early phases of the COVID-19 pandemic, although patients and physicians should be fully aware that currently there is only a non–peer-reviewed, noncomparative, observational experience (very low evidence from an unreviewed cases series), and that it only supports a potential favourable effect on inflammatory signs and symptoms, while there is no information on any possible effect on survival."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T85377","span":{"begin":60,"end":71},"obj":"Chemical"},{"id":"T73580","span":{"begin":159,"end":164},"obj":"Chemical"},{"id":"T92027","span":{"begin":529,"end":534},"obj":"Chemical"},{"id":"T54631","span":{"begin":542,"end":553},"obj":"Chemical"}],"attributes":[{"id":"A3123","pred":"chebi_id","subj":"T85377","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A92022","pred":"chebi_id","subj":"T73580","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A83092","pred":"chebi_id","subj":"T92027","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A36489","pred":"chebi_id","subj":"T54631","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"}],"text":"Owing to the lack of high-level evidence, administration of tocilizumab in patients with COVID-19 should preferentially occur within the framework of RCT. Off-label use according to local protocols and consent procedures may be considered only in those COVID-19 patients excluded from RCT (or hospitalized where RCT are not available or still to be implemented) and who are worsening while receiving standard supportive care (in the absence of concomitant/superimposed infections). In our opinion, this could be a reasonable off-label use of tocilizumab in these early phases of the COVID-19 pandemic, although patients and physicians should be fully aware that currently there is only a non–peer-reviewed, noncomparative, observational experience (very low evidence from an unreviewed cases series), and that it only supports a potential favourable effect on inflammatory signs and symptoms, while there is no information on any possible effect on survival."}

{"project":"LitCovid-sentences","denotations":[{"id":"T461","span":{"begin":0,"end":154},"obj":"Sentence"},{"id":"T462","span":{"begin":155,"end":481},"obj":"Sentence"},{"id":"T463","span":{"begin":482,"end":958},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Owing to the lack of high-level evidence, administration of tocilizumab in patients with COVID-19 should preferentially occur within the framework of RCT. Off-label use according to local protocols and consent procedures may be considered only in those COVID-19 patients excluded from RCT (or hospitalized where RCT are not available or still to be implemented) and who are worsening while receiving standard supportive care (in the absence of concomitant/superimposed infections). In our opinion, this could be a reasonable off-label use of tocilizumab in these early phases of the COVID-19 pandemic, although patients and physicians should be fully aware that currently there is only a non–peer-reviewed, noncomparative, observational experience (very low evidence from an unreviewed cases series), and that it only supports a potential favourable effect on inflammatory signs and symptoms, while there is no information on any possible effect on survival."}